Biopharm Biz Buries Hatchet Over Parkinson's Drug For $7.5M
A biopharmaceutical business decided Wednesday to buy the global rights to a rival's Parkinson's disease drug for $7.5 million in a move that also buried the hatchet on two years of...To view the full article, register now.
Already a subscriber? Click here to view full article